Collplant Biotechnologies Reports 2025 Third Quarter Financial Results

Reuters

Nov 26, 2025

Nov 26 (Reuters) - Collplant Biotechnologies Ltd ::
*COLLPLANT BIOTECHNOLOGIES REPORTS 2025 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
*COLLPLANT BIOTECHNOLOGIES 9M OPERATING EXPENSES USD 10 MILLION
*COLLPLANT BIOTECHNOLOGIES 9M ADJUSTED NET INCOME USD -7 MILLION
*COLLPLANT BIOTECHNOLOGIES 9M ADJUSTED EPS USD -0.58
*COLLPLANT BIOTECHNOLOGIES 9M REVENUE USD 2.3 MILLION
*COLLPLANT BIOTECHNOLOGIES 9M NET INCOME USD -8.3 MILLION
*COLLPLANT BIOTECHNOLOGIES 9M EPS USD -0.69
*COLLPLANT BIOTECHNOLOGIES LTD - RECENTLY UPDATED ITS EXPENSE FORECAST AND HAS INITIATED A COST CUTTING AND WORKFORCE REDUCTION PLAN
*COLLPLANT BIOTECHNOLOGIES: UPDATED ALLOCATION OF RESOURCES TO RESULT IN REDUCTION IN WORKFORCE BY ABOUT 25%
*COLLPLANT BIOTECHNOLOGIES LTD - ROGER POMERANTZ STEPS DOWN AS CHAIRMAN; YEHIEL TAL NOMINATED AS INTERIM CHAIRMAN
*COLLPLANT BIOTECHNOLOGIES LTD - ROGER POMERANTZ STEPS DOWN AS CHAIRMAN; YEHIEL TAL NOMINATED AS INTERIM CHAIRMAN

((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 26-NOV-202512:30:00.32 GMT

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2586523132"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2586523132\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2586523132?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-26 20:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2586523132","market":"nz","top_or_hot":-1,"title":"Collplant Biotechnologies Reports 2025 Third Quarter Financial Results","media":"Reuters","content":"<html><body>Nov 26 (Reuters) - Collplant Biotechnologies Ltd <cptg.f>::<br/>*COLLPLANT BIOTECHNOLOGIES REPORTS 2025 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE<br/>*COLLPLANT BIOTECHNOLOGIES 9M OPERATING EXPENSES USD 10 MILLION<br/>*COLLPLANT BIOTECHNOLOGIES 9M ADJUSTED NET INCOME USD -7 MILLION<br/>*COLLPLANT BIOTECHNOLOGIES 9M ADJUSTED EPS USD -0.58<br/>*COLLPLANT BIOTECHNOLOGIES 9M REVENUE USD 2.3 MILLION<br/>*COLLPLANT BIOTECHNOLOGIES 9M NET INCOME USD -8.3 MILLION<br/>*COLLPLANT BIOTECHNOLOGIES 9M EPS USD -0.69<br/>*<a href=\"https://laohu8.com/S/CLGN\">COLLPLANT BIOTECHNOLOGIES LTD</a> - RECENTLY UPDATED ITS EXPENSE FORECAST AND HAS INITIATED A COST CUTTING AND WORKFORCE REDUCTION PLAN<br/>*COLLPLANT BIOTECHNOLOGIES: UPDATED ALLOCATION OF RESOURCES TO RESULT IN REDUCTION IN WORKFORCE BY ABOUT 25%<br/>*COLLPLANT BIOTECHNOLOGIES LTD - ROGER POMERANTZ STEPS DOWN AS CHAIRMAN; YEHIEL TAL NOMINATED AS INTERIM CHAIRMAN<br/>*COLLPLANT BIOTECHNOLOGIES LTD - ROGER POMERANTZ STEPS DOWN AS CHAIRMAN; YEHIEL TAL NOMINATED AS INTERIM CHAIRMAN<br/><br/>  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))<br/>  Source Date/Time = 26-NOV-202512:30:00.32 GMT</cptg.f></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Collplant Biotechnologies Reports 2025 Third Quarter Financial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCollplant Biotechnologies Reports 2025 Third Quarter Financial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-26 20:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body>Nov 26 (Reuters) - Collplant Biotechnologies Ltd <cptg.f>::<br/>*COLLPLANT BIOTECHNOLOGIES REPORTS 2025 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE<br/>*COLLPLANT BIOTECHNOLOGIES 9M OPERATING EXPENSES USD 10 MILLION<br/>*COLLPLANT BIOTECHNOLOGIES 9M ADJUSTED NET INCOME USD -7 MILLION<br/>*COLLPLANT BIOTECHNOLOGIES 9M ADJUSTED EPS USD -0.58<br/>*COLLPLANT BIOTECHNOLOGIES 9M REVENUE USD 2.3 MILLION<br/>*COLLPLANT BIOTECHNOLOGIES 9M NET INCOME USD -8.3 MILLION<br/>*COLLPLANT BIOTECHNOLOGIES 9M EPS USD -0.69<br/>*<a href=\"https://laohu8.com/S/CLGN\">COLLPLANT BIOTECHNOLOGIES LTD</a> - RECENTLY UPDATED ITS EXPENSE FORECAST AND HAS INITIATED A COST CUTTING AND WORKFORCE REDUCTION PLAN<br/>*COLLPLANT BIOTECHNOLOGIES: UPDATED ALLOCATION OF RESOURCES TO RESULT IN REDUCTION IN WORKFORCE BY ABOUT 25%<br/>*COLLPLANT BIOTECHNOLOGIES LTD - ROGER POMERANTZ STEPS DOWN AS CHAIRMAN; YEHIEL TAL NOMINATED AS INTERIM CHAIRMAN<br/>*COLLPLANT BIOTECHNOLOGIES LTD - ROGER POMERANTZ STEPS DOWN AS CHAIRMAN; YEHIEL TAL NOMINATED AS INTERIM CHAIRMAN<br/><br/>  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))<br/>  Source Date/Time = 26-NOV-202512:30:00.32 GMT</cptg.f></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CLGN","symbol_name":"COLLPLANT BIOTECHNOLOGIES LTD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nRSD936k77:1","article_id":"2586523132","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2586523132","pubTimestamp":1764161478,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Nov 26 (Reuters) - Collplant Biotechnologies Ltd ::*COLLPLANT BIOTECHNOLOGIES REPORTS 2025 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE*COLLPLANT BIOTECHNOLOGIES 9M OPERATING EXPENSES","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CLGN":"COLLPLANT BIOTECHNOLOGIES LTD","BK4139":"生物科技"},"translate_title":"Collplant Biotechnologies报告2025年第三季度财务业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLGN":0.9},"content_text":"Nov 26 (Reuters) - Collplant Biotechnologies Ltd ::*COLLPLANT BIOTECHNOLOGIES REPORTS 2025 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE*COLLPLANT BIOTECHNOLOGIES 9M OPERATING EXPENSES USD 10 MILLION*COLLPLANT BIOTECHNOLOGIES 9M ADJUSTED NET INCOME USD -7 MILLION*COLLPLANT BIOTECHNOLOGIES 9M ADJUSTED EPS USD -0.58*COLLPLANT BIOTECHNOLOGIES 9M REVENUE USD 2.3 MILLION*COLLPLANT BIOTECHNOLOGIES 9M NET INCOME USD -8.3 MILLION*COLLPLANT BIOTECHNOLOGIES 9M EPS USD -0.69*COLLPLANT BIOTECHNOLOGIES LTD - RECENTLY UPDATED ITS EXPENSE FORECAST AND HAS INITIATED A COST CUTTING AND WORKFORCE REDUCTION PLAN*COLLPLANT BIOTECHNOLOGIES: UPDATED ALLOCATION OF RESOURCES TO RESULT IN REDUCTION IN WORKFORCE BY ABOUT 25%*COLLPLANT BIOTECHNOLOGIES LTD - ROGER POMERANTZ STEPS DOWN AS CHAIRMAN; YEHIEL TAL NOMINATED AS INTERIM CHAIRMAN*COLLPLANT BIOTECHNOLOGIES LTD - ROGER POMERANTZ STEPS DOWN AS CHAIRMAN; YEHIEL TAL NOMINATED AS INTERIM CHAIRMAN  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 26-NOV-202512:30:00.32 GMT","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}